Potential Biological Targets for Anti-Alzheimer Drugs
H. Allain, Serge Belliard, Jacques D. de Certaines, Danièle Bentué‐Ferrer, Michelle Bureau, Pauline M. Lacroix · Dementia and Geriatric Cognitive Disorders · 1993
The stunning accumulation of data on the physiopathology of Alzheimer's disease is a real hinderance to pharmacologists who have to make decisions as to what molecules should be assessed first in man. Considering the cumbersomeness and cost of clinical trials in that field, a review of potential targets for drugs that are supposed to be active against the disease has become necessary, for a true definition of the rational justifications of trials to be envisaged.